目的 报道10例血清CA19-9明显升高的胆管良性疾病病例。
方法 回顾性分析2004年1月至2006年3月期间我院收治并经手术证实的10例血清CA19-9明显升高（ gt;500 U/ml）的胆管良性病变病例。
结果 患者中男4例，女6例，年龄30~85岁，CA19-9为532.32~12 000.00 U/ml，除1例患者CA125轻度升高外，其他患者血清CEA、CA125及AFP均正常。胆总管结石8例，肝内胆管结石1例，原发性硬化性胆管炎1例； 除1例外均存在不同程度阻塞性黄疸。经治疗后8例CA19-9水平在30 d内降至正常，另2例分别于术后2个月和3个月内降至正常。
结论 CA19-9在胆管恶性肿瘤诊断方面的意义仍需进一步研究。
Citation：
费健,王建承,陈胜,邓漾,朱坚,张卓,许志伟,陆晔,吴卫泽,雷若庆,韩天权,张圣道. Extraordinarily Elevated CA19-9 Levels in Patients with Benign Disease of Biliary Tract (Report of 10 Cases). CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2007, 14(5): 580-582. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Minato H, Nakanuma Y, Terada T. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts [J]. Histopathology， 1996; 28(5)∶411.
|
| 2. |
Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA [J]. Ann Clin Biochem， 1998; 35(Pt 1)∶99.
|
| 3. |
Paganuzzi M, Onetto M, Marroni P, et al. CA19-9 and CA50 in benign and malignant pancreatic and biliary diseases [J]. Cancer， 1988; 61(10)∶2100.
|
| 4. |
秦兴雷， 李志强， 石景森， 等. 血清和胆汁CA19-9联合检测对诊断胆道良恶性病变的价值 [J]. 中国普外基础与临床杂志， 2000； 7(3)∶161.
|
| 5. |
Bjornsson E, Kilander A, Olsson R. CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis [J]. Liver， 1999; 19(6)∶501.
|
| 6. |
Patel AH, Harnois DM, Klee GG, et al. The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis [J]. Am J Gastroenterol， 2000; 95(1)∶204.
|
| 7. |
Robertson AG, Davidson BR. Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9 [J]. Eur J Gastroenterol Hepatol， 2007; 19(2)∶167.
|
| 8. |
Murray MD, Burton FR, Di Bisceglie AM. Markedly elevated serum CA19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis [J]. J Clin Gastroenterol， 2007; 41(1)∶115.
|
| 9. |
Katsanos KH, Kitsanou M, Christodoulou DK, et al. High CA19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature [J]. Eur J Intern Med， 2002; 13(2)∶132.
|
| 10. |
Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis [J]. Dig Dis Sci， 1988; 33(10)∶1223.
|
| 11. |
Lin CL, Changchien CS, Chen YS. Mirizzi’s syndrome with a high CA19-9 level mimicking cholangiocarcinoma [J]. Am J Gastroenterol， 1997; 92(12)∶2309.
|
| 12. |
Ogawa T, Yokoi H, Kawarada Y. A case of inflammatory pseudotumor of the liver causing elevated serum CA19-9 levels [J]. Am J Gastroenterol， 1998; 93(12)∶2551.
|
| 13. |
Trompetas V, Panagopoulos E, Ramantanis G. Gall-bladder agenesis presenting with obstructive jaundice and elevated CA19-9 [J]. Acta Chir Belg， 2004; 104(3)∶347.
|
| 14. |
Basso D, Meggiato T, Fabris C, et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases [J]. Eur J Clin Invest， 1992; 22(12)∶800.
|
- 1. Minato H, Nakanuma Y, Terada T. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts [J]. Histopathology， 1996; 28(5)∶411.
- 2. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA [J]. Ann Clin Biochem， 1998; 35(Pt 1)∶99.
- 3. Paganuzzi M, Onetto M, Marroni P, et al. CA19-9 and CA50 in benign and malignant pancreatic and biliary diseases [J]. Cancer， 1988; 61(10)∶2100.
- 4. 秦兴雷， 李志强， 石景森， 等. 血清和胆汁CA19-9联合检测对诊断胆道良恶性病变的价值 [J]. 中国普外基础与临床杂志， 2000； 7(3)∶161.
- 5. Bjornsson E, Kilander A, Olsson R. CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis [J]. Liver， 1999; 19(6)∶501.
- 6. Patel AH, Harnois DM, Klee GG, et al. The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis [J]. Am J Gastroenterol， 2000; 95(1)∶204.
- 7. Robertson AG, Davidson BR. Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9 [J]. Eur J Gastroenterol Hepatol， 2007; 19(2)∶167.
- 8. Murray MD, Burton FR, Di Bisceglie AM. Markedly elevated serum CA19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis [J]. J Clin Gastroenterol， 2007; 41(1)∶115.
- 9. Katsanos KH, Kitsanou M, Christodoulou DK, et al. High CA19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature [J]. Eur J Intern Med， 2002; 13(2)∶132.
- 10. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis [J]. Dig Dis Sci， 1988; 33(10)∶1223.
- 11. Lin CL, Changchien CS, Chen YS. Mirizzi’s syndrome with a high CA19-9 level mimicking cholangiocarcinoma [J]. Am J Gastroenterol， 1997; 92(12)∶2309.
- 12. Ogawa T, Yokoi H, Kawarada Y. A case of inflammatory pseudotumor of the liver causing elevated serum CA19-9 levels [J]. Am J Gastroenterol， 1998; 93(12)∶2551.
- 13. Trompetas V, Panagopoulos E, Ramantanis G. Gall-bladder agenesis presenting with obstructive jaundice and elevated CA19-9 [J]. Acta Chir Belg， 2004; 104(3)∶347.
- 14. Basso D, Meggiato T, Fabris C, et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases [J]. Eur J Clin Invest， 1992; 22(12)∶800.
